Alpha 2.0
Login Register
» Articles » PMID: 27573173

Structural Basis of Anti-PD-L1 Monoclonal Antibody Avelumab for Tumor Therapy

Overview
Journal Cell Res
Specialty Cell Biology
Date 2016 Aug 31
PMID 27573173
Citations 68
Authors
Kefang Liu
Shuguang Tan
Yan Chai
Danqing Chen
Hao Song
Catherine Wei-Hong Zhang
Yi Shi
Jun Liu
Wenjie Tan
Jianxin Lyu
Shan Gao
Jinghua Yan
Jianxun Qi
George F Gao
Affiliations
Soon will be listed here.
Citing Articles

Activation of T Lymphocytes with Anti-PDL1-BiTE in the Presence of Adipose-Derived Mesenchymal Stem Cells (ASCs).

Moeinzadeh L, Ramezani A, Mehdipour F, Yazdanpanah-Samani M, Razmkhah M Biomed Res Int. 2024; 2023:7692726.

PMID: 39282109 PMC: 11401667. DOI: 10.1155/2023/7692726.

An in silico investigation on the binding site preference of PD-1 and PD-L1 for designing antibodies for targeted cancer therapy.

Abdolmaleki S, Ganjalikhani Hakemi M, Ganjalikhany M PLoS One. 2024; 19(7):e0304270.

PMID: 39052609 PMC: 11271968. DOI: 10.1371/journal.pone.0304270.

Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities.

Badenhorst M, Windhorst A, Beaino W Front Med (Lausanne). 2024; 11:1401515.

PMID: 38915766 PMC: 11195831. DOI: 10.3389/fmed.2024.1401515.

PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET.

Ibrahim D, Simo C, Brown E, Shmuel S, Panikar S, Benton A Front Immunol. 2024; 15:1405485.

PMID: 38915392 PMC: 11194338. DOI: 10.3389/fimmu.2024.1405485.

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1.

Malinge P, Chauchet X, Bourguignon J, Bosson N, Calloud S, Bautzova T MAbs. 2024; 16(1):2362432.

PMID: 38849989 PMC: 11164222. DOI: 10.1080/19420862.2024.2362432.

References
1.
Lin D, Tanaka Y, Iwasaki M, Gittis A, Su H, Mikami B . The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci U S A. 2008; 105(8):3011-6. PMC: 2268576. DOI: 10.1073/pnas.0712278105. View
2.
Chen Y, Liu P, Gao F, Cheng H, Qi J, Gao G . A dimeric structure of PD-L1: functional units or evolutionary relics?. Protein Cell. 2011; 1(2):153-60. PMC: 4875164. DOI: 10.1007/s13238-010-0022-1. View
3.
Powles T, Eder J, Fine G, Braiteh F, Loriot Y, Cruz C . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528):558-62. DOI: 10.1038/nature13904. View
4.
Zak K, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B . Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure. 2015; 23(12):2341-2348. PMC: 4752817. DOI: 10.1016/j.str.2015.09.010. View
5.
Maute R, Gordon S, Mayer A, McCracken M, Natarajan A, Ring N . Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A. 2015; 112(47):E6506-14. PMC: 4664306. DOI: 10.1073/pnas.1519623112. View